Recursion Pharmaceuticals (RXRX)
$6.53 2%
to add to portfolio
AI Score
-
Alternative
9 -
Fundamental
9 -
Technical
4
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on Recursion Pharmaceuticals, AI stock picks, stock alerts and much more.
RXRX AI Stock Analysis
Financial Performance
Recursion Pharmaceuticals' financial performance has been showing positive growth with revenue of $26.1M, which is up by 80.9% from the previous quarter and up by a significant 139.5% year over year. The gross profit was $14M, indicating a massive increase of 962.4% from the previous quarter and an impressive hike of 211.2% YoY. However, their operating income stands at -$98.4M, though it's slightly better than the previous quarter (up by 2.2%) and YoY (up by 9.9%). Their EBITDA ratio in the last quarter was -3.37, suggesting that they are not yet profitable.
Stock Price
The stock price is currently trading at $6.88, down by -1% in the last month and considerably down by -38.4% YoY which shows a bearish trend for Recursion Pharmaceuticals' stock price performance over time despite its revenue growth and gross profit improvements.The RSI value stands at neutral level of around 45 implying neither oversold nor overbought condition while its PE ratio is at -4.47 indicating lack of profitability.
Alternative Data Signals
The company's web traffic has seen an upward trend with an estimated increase of about 45%, MoM basis along with job openings increasing substantially to around 420%, YoY basis reflecting potential expansion plans or business growth opportunities ahead.On social media front,the number of followers on Twitter have increased significantly over past few months indicating growing interest among public about this company.However,the marginal increase in Facebook followers suggests limited engagement there.Employees seem to have a positive outlook towards business as suggested by their feedback.
Conclusion
In conclusion, despite the bearish trend in stock price and lack of profitability currently, Recursion Pharmaceuticals shows promising growth potential with its impressive revenue growth, expansion plans indicated by increased job openings and positive employee outlook. Hence, the AI analysis is neutral to slightly bullish for Recursion Pharmaceuticals' stock.
Note: This AI Stock Analysis is based on data as of January 11. Our members can refresh and get access to an up-to-date AI stock analysis.
Sign up
RXRX Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Recursion Pharmaceuticals (RXRX), currently trading at $6.53, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About RXRX
-
Recursion Pharmaceuticals, Inc.
-
Symbol
RXRX
-
Market
NASDAQ
-
Industry
Biotechnology
-
Market Cap
2.5B
Similar Stocks
 |
Catalyst Pharmaceuticals CPRX |
$22.78 0.5% |
6 |
 |
Inovio Pharmaceuticals INO |
$2.08 8.9% |
4 |
 |
Moderna MRNA |
$34.06 0.9% |
4 |
 |
Anavex Life Sciences AVXL |
$9.21 9.3% |
6 |
 |
BridgeBio Pharma BBIO |
$33.79 0.9% |
7 |
News
RXRX Alternative Data
News Mentions
Sign up to access
Twitter Followers
Sign up to access
Facebook Engagement
Sign up to access
Youtube Subscribers
Sign up to access
Job Postings
Sign up to access
Web Traffic
Sign up to access
Business Outlook
Sign up to access
LinkedIn Employees
Sign up to access
RXRX Financials
RXRX Key Metrics
-
Total Revenue
$26.1M
-
Net Income
-$95.7M
-
Earnings per Share
-$0.0003
-
Free cash flow
-$60.8M
-
EBITDA
-$98.4M
-
EBITDA Ratio
-3.77095
-
Total Assets
$726.5M
RXRX 2-year Revenue & Income
RXRX 2-year Free Cash Flow
RXRX Technicals
RXRX SMA
RXRX RSI
FAQ
What's the current price of Recursion Pharmaceuticals (RXRX) Stock?
The price of an Recursion Pharmaceuticals (RXRX) share is $6.53.
What's the market cap of Recursion Pharmaceuticals?
The current market cap of Recursion Pharmaceuticals is 2.5B.
Should I buy or sell RXRX?
Multiple alternative data signals suggest that Recursion Pharmaceuticals stock could offer a buying opportunity at its current level, with a reasonable expectation for positive performance in the mid term.
Is Recursion Pharmaceuticals a good investment?
Based on an in-depth analysis that encompasses fundamentals, technical analysis, and alternative data insights, it appears to be a favorable time to consider investing in Recursion Pharmaceuticals stock. The bullish indicators suggest that Recursion Pharmaceuticals' growth prospects and market position may lead to a positive performance in the foreseeable future.
Is now a good time to buy Recursion Pharmaceuticals (RXRX) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, it could be a favorable time to consider buying Recursion Pharmaceuticals stock, given the bullish outlook.
What are some stocks similar to Recursion Pharmaceuticals (RXRX) that investors often compare it to?
Recursion Pharmaceuticals (RXRX) is often compared to similar stocks such as Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Moderna, Anavex Life Sciences and BridgeBio Pharma.
What is the forecast for Recursion Pharmaceuticals' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Recursion Pharmaceuticals' stock price to be around $7 in 2026. Starting from the current price of $6.53, this represents a 7.3% change in price, indicating a bullish outlook for the stock.
How to buy Recursion Pharmaceuticals (RXRX) Stock?
Recursion Pharmaceuticals stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Recursion Pharmaceuticals shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.